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Abstract
Background: Better biomarkers for assessing risk of relapse in stage I testicular germ cell tumor patients are
needed, to complement classical histopathological variables. We aimed to assess the prognostic value of previously
suggested biomarkers, related to proliferation (MIB-1 and TEX19) and to immune microenvironment (CXCL12,
CXCR4, beta-catenin and MECA-79) in a surveillance cohort of stage I testicular germ cell tumor patients.
Methods: A total of 70 patients were included. Survival analyses were performed, including Cox regression models.
Results: Patients with vascular invasion and elevated human chorionic gonadotropin levels showed significantly
poorer relapse-free survival in multivariable analysis (hazard ratio = 2.820, 95% confidence interval 1.257–6.328;
hazard ratio = 3.025, 95% confidence interval 1.345–6.808). Patients with no vascular invasion but with MIB-1
staining in > 50% tumor cells showed significantly shorter relapse-free survival (p = 0.042). TEX19 nuclear
immunoexpression was confirmed in spermatogonial cells, and weak cytoplasmic immunoexpression was depicted
in 15/70 tumors, not significantly impacting survival. CXCL12 immunoexpression in tumor cells did not associate
with relapse, but non-seminoma patients exhibiting vascular invasion and CXCL12-positive stromal/inflammatory
cells showed significantly improved relapse-free survival (p = 0.015). Exclusively nuclear immunoexpression of CXCR4
associated with better relapse-free survival (p = 0.032), but not after adjusting for vascular invasion. Patients with
higher beta-catenin scores showed a tendency for poorer relapse-free survival (p = 0.056). MECA-79
immunoexpression was absent.
Conclusions: The informative protein biomarkers (i.e., MIB-1, CXCL12, beta-catenin, and possibly CXCR4) may prove
useful for risk-stratifying patients if validated in larger, multicentric and well-defined studies. Currently, classical
histopathological features of testicular germ cell tumors remain key for relapse prediction.
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Background
Testicular germ cell tumors are among the most com-
mon solid neoplasms in young-adult males. Their overall
good prognosis puts them on the top of most curable
solid cancers, with survival rates above 85–90% [1].
Around 85% and 70–75% of stage I seminoma and non-
seminoma patients, respectively, are cured with orchiec-
tomy alone [2–5], meaning that a substantial amount of
patients can be safely followed-up using surveillance,
which is indeed being increasingly adopted [6]. However,
still a subgroup of these patients relapses, most fre-
quently during the first 2 years after initial diagnosis,
and requires further treatments, which possibly lead to
morbidity and mortality [7, 8]. For this reason, there is
an urgent need for predictive biomarkers to assess the
risk of stage I patients, and accurately discriminate those
truly benefiting from adjuvant treatment to prevent re-
lapses, from those that can safely be followed using sur-
veillance to avoid early and late side effects of additional
treatments on individuals most likely becoming long-
term cancer survivors [9–11].
This risk stratification of stage I patients has so far relied
on clinicopathological parameters, predominantly being
vascular invasion and the amount of embryonal carcinoma
(for non-seminomas) [12, 13] and size and rete testis inva-
sion (for seminomas) [14]. With the exception of vascular
invasion for non-seminomas, the prognostic power of the
other biomarkers to guide treatment decisions is still
under debate [14, 15]. Vascular invasion is the most dis-
criminative biomarker so far, even in multivariable ana-
lyses [12, 13]. Recently, we confirmed the value of vascular
invasion assessment in a surveillance cohort of stage I
non-seminoma patients [16]. Moreover, we demonstrated
that all patients depicting simultaneously lymph vessel
and blood vessel invasion developed relapse; possibly, if
validated, this should further identify high-risk patients.
Overall, accurate pathological assessment is key since
overdiagnosis (commonly observed in vascular invasion
assessment by less experienced centers) may result in
overtreatment [17, 18].
Other biomarkers have been studied for their prognos-
tic/predictive value in testicular germ cell tumors, includ-
ing MIB-1, CXCL12, CXCR4 and beta-catenin [19–22].
However, none has been introduced in the clinic yet, pos-
sibly since results among studies were not consistent or
reflecting the variability among study designs. MECA-79
is another biomarker shown to be involved in antitumor
responses in some malignancies, although so far not been
explored in testicular germ cell tumors [23–25]. Also, for
TEX19, a cancer testis antigen present in normal adult
testis and involved in proliferation of several cancer types
and of germ cells [26], its expression profile in testicular
germ cell tumors has not been demonstrated yet. In this
work we aim to assess the prognostic value of biomarkers
related to proliferation (MIB-1, TEX19) and to the sur-
rounding immune microenvironment (CXCL12, CXCR4,
beta-catenin and MECA-79) in a cohort of stage I testicu-
lar germ cell tumor patients undergoing surveillance, in-
cluding their impact in patient outcome, and to compare




Patients undergoing orchiectomy and diagnosed with stage
I testicular germ cell tumors (in the period between the
years 1993–2018) were retrospectively queried from our
dataset, which includes patients undergoing orchiectomy in
several hospitals across the Netherlands. Pediatric (type I)
and spermatocytic (type III) tumors were excluded (i.e.
postpubertal, type II tumors, either seminomas or non-
seminomas, were included). Only patients assigned to sur-
veillance strategy (i.e. absence of any adjuvant treatment
after the orchiectomy) were included in the study. Clinical
files were reviewed by a clinician (WE) blinded to all the
analyses performed. The following variables were collected:
dates of birth, age and serum tumor biomarkers at diagno-
sis; histological subtype, laterality, size, presence of vascular
invasion and rete testis invasion; treatment of relapses (sur-
gery and/or chemotherapy); type and topography of re-
lapses; and diagnosis, relapse, death and date of last follow-
up. Relapse was categorized as “early” or “late” as indicated
elsewhere, with a cutoff of 2 years after treatment [27]. Pa-
tients without the required clinical data were excluded.
Orchiectomy specimens were fixed overnight in 10%
buffered formalin and representative sections were col-
lected and paraffin embedded. All cases were histologi-
cally assessed by a germ cell tumor-dedicated
Pathologist with decades of experience (JWO). Represen-
tative blocks (containing at least 1cm2 of tumor and
interface with adjacent non-involved parenchyma) were
selected for evaluation, of which serial 4-μm sections
were cut and used for immunohistochemistry.
Use of patient samples was approved for research by
the Medical Ethical Committee of the EMC (the
Netherlands), permit no. 02.981. Samples were used ac-
cording to the “Code for Proper Secondary Use of Hu-
man Tissue in The Netherlands” developed by the
Dutch Federation of Medical Scientific Societies
(FMWV, version, 2002; update 2011).
Immunohistochemistry
Immunohistochemistry was performed with an auto-
mated, validated and accredited staining system (Ven-
tana Benchmark ULTRA, Ventana Medical Systems,
Tucsen, AZ, USA) using the optiview universal DAB de-
tection Kit (cat.760–700, Ventana Medical Systems) or
Ultraview detection kit (cat.760–500, Ventana Medical
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Systems). In brief, following deparaffinization and heat-
induced antigen retrieval the tissue samples were incu-
bated according to their optimized time with the anti-
body of interest (Supplementary Table 1). Incubation
was followed by hematoxylin II counter stain for 12 min
and then a blue colouring reagent for 8 min according to
the manufactures instructions (Ventana Medical Sys-
tems, Tucsen, AZ, USA).
Scoring of immunostainings
Scoring of immunostainings was performed by a germ cell
tumor-dedicated investigator (J.L.), blinded to the clinical
outcome/data of each case. Both the intensity (0, 1, 2 and 3,
corresponding to absent, weak, intermediate and strong
staining) and percentage of stained tumor cells were
assessed independently, as done in previous studies asses-
sing these markers. “weak”, “intermediate” and “strong” was
defined as indicated in [28]. Overall assessment was re-
ported for mixed tumors, since 17/23 consisted of tumors
with > 90% embryonal carcinoma, with only small foci of
cells from other distinct subtypes. The cellular localization
of the staining was also annotated. For CXCL12, addition-
ally to the staining in tumor cells, surrounding stromal/in-
flammatory cells were also scored by the same method.
The final (relevant) scoring method of each immunostain-
ing was then adjusted based on the overall staining patterns
and to allow maximum comparability to previous studies
(see below in the Results section).
Statistical analysis
Data was tabulated using Microsoft Excel 2016 and ana-
lyzed using IBM SPSS Statistics version 24. Percentages
were calculated based on the number of cases with avail-
able data and continuous variables were described as
median plus interquartile range. Clinicopathological cor-
relates were assessed for all samples and also within each
histological subtype, and significant findings were re-
ported. Associations between categorical variables were
assessed using chi-square or Fisher exact test, as appro-
priate. Distribution of continuous variables (age and
size) among groups was compared using the nonpara-
metric Mann-Whitney U test. Survival analyses were
computed with Kaplan-Meier estimator and log-rank
test. Hazard ratios and respective 95% confidence inter-
vals were estimated using Cox regression models. Statis-
tical significance was set at p ≤ 0.05.
Results
Cohort characterization and impact of the various
clinicopathological variables on patient outcome
A total of 70 patients met the including criteria of the
study, 28 with seminoma and 42 with non-seminoma
(detailed clinicopathological characterization of patients
and tumor samples is depicted in Table 1, and separately
for seminoma/non-seminoma in Table 2). Median follow-
up time was 42months. The median patient age at diag-
nosis was 32 years (interquartile range 28–39), 35 for
seminoma and 26 for non-seminoma patient. Among
non-seminomas, the most frequent histologies were mixed
tumors (23/42, 54.8%, with embryonal carcinoma compo-
nents being absent in only six of these), followed by pure
embryonal carcinoma (16/42, 38.1%, due to special enrich-
ment of the cohort for this histology). Overall, 28 patients
(40.0%) developed relapse during the follow-up time, eight
seminomas (28.6%) and 20 non-seminomas (47.6%). There
were four late relapses (at 29, 27, 25 and just over 24
months), all corresponding to seminoma patients with re-
currence of disease in retroperitoneal lymph-nodes, and
one died of disease. There was a tendency for seminomas
to be diagnosed in later age compared to non-seminomas
(median age 35 vs. 30 years, p = 0.059). Non-seminomas
depicted more frequently vascular invasion (p = 0.002),
but there were no significant differences in tumor size or
proportion of rete testis invasion.
Overall, considering all patients (i.e. seminoma and
non-seminoma), vascular invasion, rete testis invasion
and elevation of human chorionic gonadotropin (HCG)
were significantly associated with one another (vascular
invasion vs. rete testis invasion: p < 0.001; vascular inva-
sion vs. HCG elevation: p = 0.005), and all individually
associated with disease relapse (p < 0.001, p = 0.009, p =
0.001, respectively). No significant associations were
found between disease recurrence and histological sub-
type, alpha fetoprotein (AFP) elevation, tumor size or
age at diagnosis. Regarding survival analysis, patients
with vascular invasion experienced a worse relapse-free
survival compared to those with no vascular invasion
(hazard ratio 4.028, 95% confidence interval 1.868–
8.682, p < 0.001), as did patients with rete testis invasion
(hazard ratio 3.373, 95% confidence interval 1.545–
7.364, p = 0.002) and elevation of HCG (hazard ratio
4.245, 95% confidence interval 1.964–9.178, p < 0.001)
(Fig. 1a-c). The remaining variables did not show an im-
pact of relapse-free survival. In multivariable analysis,
vascular invasion showed an independent impact in
relapse-free survival when adjusting for the effect of rete
testis invasion (hazard ratio 2.864, 95% confidence inter-
val 1.225–6.697, p = 0.015); when adjusting for the effect
of HCG elevation, both variables remain significant (vas-
cular invasion: hazard ratio 2.820, 95% confidence inter-
val 1.257–6.328, p = 0.012; HCG: hazard ratio 3.025, 95%
confidence interval 1.345–6.808, p = 0.007).
When stratifying the analysis according to histology,
vascular invasion was found to be significantly associated
with relapse in non-seminomas (p = 0.003), but not in
seminoma patients (p = 0.555), while rete testis invasion
and tumor size did not significantly associate with re-
lapse in any of the groups, individually (p = 0.136 and
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p = 0.308 in seminomas; p = 0.060 and p = 0.477 in non-
seminomas). Regarding all the non-seminoma patients,
presence of embryonal carcinoma significantly associated
with relapse as well (p = 0.022). In the next two sections
the other findings based on immunohistochemistry will
be presented, classified into two main categories, being
related to proliferation (MIB-1 and TEX-19) and
immune-micro-environment (CXCL12, CXCR4, beta-
catenin, MECA-79). q.
Biomarkers related to proliferation
MIB-1 scoring
Regarding MIB-1 scoring, intensity of staining (nuclear)
was always high and did not vary among tumor samples,
so we focused on the proportion of cells staining, like
performed routinely for several tumor models (such as
breast cancer [29]). The 40 and 70% cutoffs were
assessed for comparability with previous studies on tes-
ticular germ cell tumors, and additionally other cutoffs
were tested [21, 30, 31].
Regarding the whole cohort of stage I patients, and
considering referred cutoffs, there was no significant as-
sociation between MIB-1 staining percentage and the
event of relapse (p = 0.127). Although the relapse-free
survival at 2 years was better for patients with ≤70%
MIB-1 staining compared to those with > 70% staining
(79% vs. 55%), the overall difference was not significant
(p = 0.139). However, when considering the 50% cutoff,
MIB-1 staining proportion significantly associated with
relapse (p = 0.028, Table 3). Of the patients developing
recurrence only 7% showed MIB-1 staining in ≤50% of
the tumor cells. Patients with ≤50% MIB-1 staining ex-
perienced better relapse-free survival (p = 0.049, Fig. 2a).
When adjusting for the effect of vascular invasion, MIB-
1 staining loses its impact on relapse-free survival, and
only vascular invasion remains significant (hazard ratio
3.628, 95% confidence interval 1.678–7.843, p = 0.001).
However, when considering only patients without vascu-
lar invasion, MIB-1 staining further stratified the pa-
tients according to relapse-free survival, with those
showing > 50% expression experiencing worse outcome
(p = 0.042, Fig. 2b, Fig. 3). Besides the MIB-1 staining be-
ing significantly associated with vascular invasion in
Table 1 Clinicopathological features of stage I testicular germ
cell tumor patients put on surveillance strategy
Variables Cohort
(n = 70)




Pre-operative serum AFP (n, %)
Within normal range 49/70 (70.0)
Elevated 21/70 (30.0)
Pre-operative serum β-HCG (n, %)
Within normal range 43/69 (62.3)
Elevated 26/69 (37.7)
Histologic subtypes (n, %)
Pure seminoma 28/70 (40.0)
Pure embryonal carcinoma 16/70 (22.9)
Pure postpubertal-type yolk sac tumor 1/70 (1.4)
Pure postpubertal-type teratoma 2/70 (2.9)
Mixed tumor, with embryonal carcinoma component 17/70 (24.3)
Mixed tumor, without embryonal carcinoma component 6/70 (8.5)
Tumor size [cm (median, interquartile range)] 3.0 (2.0–4.3)
Rete testis invasion (n, %)
Absent 50/66 (75.8)
Present 16/66 (24.2)






Type of relapse (n, %)
Early 24/28 (85.7)
Late 4/28 (14.3)
Site of relapse (n, %)
Only serum markers 7/28 (25.0)
Serum markers + PAoLN 6/28 (21.4)
Serum markers + Lung 2/28 (7.2)
Only PAoLN 9/28 (32.1)
Only Lung 3/28 (10.7)
PAoLN + Lung 1/28 (3.6)
Treatment performed for relapses (n, %)
Refused therapy 1/28 (3.6)
Only chemotherapy (+/− radiotherapy) 23/28 (82.1)
Chemotherapy + RPLND 3/28 (10.7)
Chemotherapy + Lung resection 1/28 (3.6)
Vital status at last follow-up (n, %)
Table 1 Clinicopathological features of stage I testicular germ






Abbreviations: AFP alpha fetoprotein, A-NED alive with no evidence of disease,
β-HCG human chorionic gonadotropin subunit beta, DFD died from disease, D-
NED died with no evidence of disease, PAoLN para-aortic lymph-nodes, RPLND
retroperitoneal lymph-node dissection
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non-seminoma patients only (p = 0.014), it was not sig-
nificantly associated with other pathological variables
(histological type, vascular invasion, rete testis invasion,
or tumor size).
TEX19 scoring
TEX19 staining was found infrequently in our cohort
(15/70, 21.4%), invariably corresponded to low intensity
cytoplasmic staining in tumor cells and, in all cases but
one, < 30% of cells showed expression (the exception be-
ing a single case of pure embryonal carcinoma with posi-
tivity in 80% of cells). In the absence of a reported cutoff
we categorized cases as “positive” vs. “negative”. Nuclear
staining was not seen on tumor cells.
Adjacent testicular parenchyma invariably showed
strong cytoplasmic staining in cells in a basal position
within the seminiferous tubule, corresponding to Sertoli
cells. Small punctate foci of nuclear positivity were de-
noted in some scattered spermatogonial cells in normal
testis (Supplementary Fig. 1).
Positivity was significantly more common in non-
seminomas (p = 0.003, Table 3), with only one seminoma
patient showing faint staining in tumor cells. There were
no significant associations with the remaining patho-
logical variables and expression did not associate signifi-
cantly with disease relapse. Relapse-free survival at 5
months was of 72% for negative patients and of 53% for
positive patients, but overall the impact on relapse-free
survival did not reach statistical significance (Supple-
mentary Fig. 2A).
Biomarkers related to the immune microenvironment
CXCL12 scoring
When present, CXCL12 expression was always mem-
brane/cytoplasmic (both in tumor and stromal/inflam-
matory cells), and was invariably strong in intensity, but
occurring in a variable proportion of cells. According to
the previous study, the 1 and 10% cutoffs were used to
categorize the cases [21].
A total of 23 (32.9%) and 49 (70.0%) tumors showed
expression of CXCL12 in tumor cells and surrounding
stromal/inflammatory cells. Expression in tumor cells
was significantly associated with non-seminoma hist-
ology (p < 0.001, Table 3), with only one seminoma case
showing expression of the biomarker; no significant as-
sociations with other pathological variables were
depicted, and expression (using both above mentioned
cutoffs) did not associate with recurrence and did not
show significant impact on relapse-free survival (p =
0.681, Supplementary Fig. 2B). The same was observed
when stratifying the patients under investigation accord-
ing to vascular invasion status. CXCL12 positivity in sur-
rounding stromal/inflammatory cells (which was
depicted in 22 seminoma and 27 non-seminoma pa-
tients) did not significantly associate with any histo-
pathological variable; however, in non-seminoma
patients specifically, it associated significantly with an
improved relapse-free survival (p = 0.039, Fig. 2c). More-
over, this effect further stratified patients exhibiting vas-
cular invasion, with those showing positivity for
CXCL12 in immediate surrounding cells displaying bet-
ter relapse-free survival (p = 0.015, Fig. 2d, Fig. 3).
CXCR4 scoring
CXCR4 expression in tumor cells was diffuse (90–100%
of cells) in all but three (pure) seminomas. Intensity and
location of staining was variable across tumor samples.
Strong (vs. low/moderate) immunostaining intensity as-
sociated with non-seminoma histology (p = 0.021), but
did not associate with the remaining pathological vari-
ables nor the event of relapse, and did not significantly
influence relapse-free survival. Thirty-three tumors
(47.1%) showed both cytoplasmic/membrane and nu-
clear expression of CXCR4, while 30 tumors (42.9%, 21
seminomas and nine non-seminomas) had exclusive
Table 2 Clinicopathological features of stage I seminoma/non-seminoma patients put on surveillance strategy
Variables Seminomas (n = 28) Non-seminomas (n = 42) p-value
Age [years (median, interquartile range)] 35 (31–40) 30 (26–39) 0.059
Tumor size [cm (median, interquartile range)] 2.5 (1.3–4.1) 3.2 (2.0–5.0) 0.113
Rete testis invasion (n, %) 0.367
Absent 22/27 (81.5) 28/39 (71.8)
Present 5/27 (18.5) 11/39 (28.2)
Vascular invasion (n, %) 0.002
Absent 24/28 (85.7) 20/41 (48.8)
Present 4/28 (14.3) 21/41 (51.2)
Relapse (n, %) 0.111
No 20/28 (71.4) 22/42 (52.4)
Yes 8/28 (28.6) 20/42 (47.6)
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Fig. 1 Kaplan-Meier curves regarding relapse-free survival in the stage I patient cohort on surveillance, according to clinicopathological features. a
- vascular invasion; b - rete testis invasion; c - HCG elevation. Abbreviations: HCG – human chorionic gonadotropin
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Table 3 Immunoexpression of the several putative prognostic markers and associations with major clinicopathological variables
Clinicopathological variables MIB-1 ≤ 50% MIB-1 > 50% p-value
Relapse (% within relapse)
No 12/42 (28.6) 30/42 (71.4) 0.028a
Yes 2/28 (7.1) 26/28 (92.9)
Histology (% within histology)
Seminoma 4/28 (14.3) 24/28 (85.7) 0.329
Non-seminoma 10/42 (23.8) 32/42 (76.2)
Vascular invasion (% within vascular invasion)
No 11/44 (25.0) 33/44 (75.0) 0.197
Yes 3/25 (12.0) 22/25 (88.0)
Clinicopathological variables TEX19 negative TEX19 positive p-value
Relapse (% within relapse)
No 34/42 (81.0) 8/42 (19.0) 0.552
Yes 21/28 (75.0) 7/28 (25.0)
Histology (% within histology)
Seminoma 27/28 (96.4) 1/28 (3.6) 0.003a
Non-seminoma 28/42 (66.7) 14/42 (33.3)
Vascular invasion (% within vascular invasion)
No 32/44 (72.7) 12/44 (27.3) 0.139
Yes 22/25 (88.0) 3/25 (12.0)
Clinicopathological variables CXCL12 negative (tumor cells) CXCL12 positive (tumor cells) p-value
Relapse (% within relapse)
No 27/42 (64.3) 15/42 (35.7) 0.533
Yes 20/28 (71.4) 8/28 (28.6)
Histology (% within histology)
Seminoma 27/28 (96.2) 1/28 (3.6) < 0.001a
Non-seminoma 20/42 (47.6) 22/42 (52.4)
Vascular invasion (% within vascular invasion)
No 30/44 (68.2) 14/44 (31.8) 0.723
Yes 16/25 (64.0) 9/25 (36.0)
Clinicopathological variables CXCR4 weak/moderate CXCR4 strong p-value
Relapse (% within relapse)
No 8/42 (19.0) 34/42 (81.0) 0.506
Yes 3/28 (10.7) 25/28 (89.3)
Histology (% within histology)
Seminoma 8/28 (28.6) 20/28 (71.4) 0.021a
Non-seminoma 3/42 (7.1) 39/42 (92.9)
Vascular invasion (% within vascular invasion)
No 8/44 (18.2) 36/44 (81.8) 0.734
Yes 3/25 (12.0) 22/25 (88.0)
Clinicopathological variables CXCR4 nuclear exclusive CXCR4 non-nuclear exclusive p-value
Relapse (% within relapse)
No 22/42 (52.4) 20/42 (47.6) 0.049a
Yes 8/28 (28.6) 20/28 (71.4)
Histology (% within histology)
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Table 3 Immunoexpression of the several putative prognostic markers and associations with major clinicopathological variables
(Continued)
Seminoma 21/28 (75.0) 7/28 (25.0) < 0.001a
Non-seminoma 9/42 (21.4) 33/42 (78.6)
Vascular invasion (% within vascular invasion)
No 26/44 (59.1) 18/44 (40.9) < 0.001a
Yes 3/25 (12.0) 22/25 (88.0)
Clinicopathological variables Beta catenin score ≤ 100 Beta catenin score > 100 p-value
Relapse (% within relapse)
No 11/42 (26.2) 31/42 (73.8) 0.045a
Yes 2/28 (7.1) 26/28 (92.9)
Histology (% within histology)
Seminoma 11/28 (39.3) 17/28 (60.7) < 0.001a
Non-seminoma 2/42 (4.8) 40/42 (95.2)
Vascular invasion (% within vascular invasion)
No 8/44 (18.2) 36/44 (81.8) 1.0
Yes 4/25 (16.0) 21/25 (84.0)
a Significant values
Fig. 2 Kaplan-Meier curves regarding relapse-free survival in the stage I patient cohort on surveillance, according to immunoexpression of several
markers. a - MIB-1 scoring using the 50% cutoff; b - MIB-1 scoring using the 50% cutoff (sub-analysis in patients with no vascular invasion only); c
- CXCL12 positivity in surrounding stromal/inflammatory cells (sub-analysis of non-seminoma patients only); d - CXCL12 positivity in surrounding
stromal/inflammatory cells (sub-analysis of non-seminoma patients displaying vascular invasion only); e - CXCR4 staining pattern in tumor cells
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nuclear staining. Seven tumors (all non-seminomas, of
which five relapsed) showed exclusive expression on the
cell membrane, without nuclear localization. Adjacent
seminiferous tubules exhibited invariable nuclear expres-
sion of this marker. Exclusive nuclear immunoexpression
(vs. other patterns) of CXCR4 significantly associated with
seminoma histology (p < 0.001), absent vascular invasion
(p < 0.001), absent rete testis invasion (p = 0.005) and ab-
sence of disease relapse (p = 0.049, Table 3). Patients with
nuclear-only staining experienced a significantly improved
relapse-free survival (hazard ratio 2.459, 95% confidence
interval 1.079–5.607, p = 0.032, Fig. 2e). However, in mul-
tivariable analysis, only vascular invasion maintains an in-
dependent impact (hazard ratio 3.496, 95% confidence
interval 1.503–8.134, p = 0.004).
Beta-catenin scoring
Regarding beta-catenin immunostaining patterns, mem-
brane staining of tumor cells (and also of adjacent tubules,
when present) was observed in all cases, with varying in-
tensity and proportion. Hence, like reported before, we
considered a combined multiplicative score of “intensity”
x “percentage of stained cells”, and cases were then further
grouped as “score ≤ 100” (hereon designated “low score”)
and “score > 100” (hereon designated “high score”) [20].
Overall, a higher beta-catenin expression score signifi-
cantly associated with non-seminoma histology (p <
0.001, Table 3) and with the event of relapse (p = 0.045),
and did not associate significantly with the remaining
pathological variables. Of all patients that developed re-
lapse, only two (7%) had a low score, compared to 26
(93%) showing high score. In survival analysis, patients
with higher score show a tendency for poorer relapse-
free survival, although it did not achieve statistical sig-
nificance (p = 0.056, Supplementary Fig. 2C).
MECA-79 scoring
MECA-79 was not found to be expressed in tumor cells
of the included samples. Also, MECA-79-positive vessels
were absent in all the samples tested.
Representative pictures of the staining patterns of the
various markers are depicted in Figs. 4 and 5 and in
Supplementary Figs. 3 and 4. Storage time did not sig-
nificantly influence the staining intensity/percentage
across samples (Supplementary Fig. 5).
Discussion
Testicular germ cell tumors are diagnostically challenging,
especially because optimal pathological assessment of the
primary tumor is key to determine the best therapeutic
approach, predominantly in stage I disease [32]. In fact,
accurate discrimination of high vs. low risk stage I patients
is essential, in order to facilitate treatment decisions and
avoid unnecessary side effects from chemotherapy and
radiation as well as surgery. Assessment of this risk status
has been largely dependent on histopathological variables,
with vascular invasion being the most consistent prognos-
tic tool for predicting disease relapse [22]. However, dis-
agreements in scoring vascular invasion exist, more
evident between peripheral and centralized centers with
expertise on germ cell tumors, and these could result in
over- and undertreatment [17, 18, 33]. Surveillance strat-
egies are increasingly being employed in the approach to
testicular germ cell tumor patients, given the outstanding
cure rates of stage I disease with orchiectomy alone [6].
Still, there is a need of adjunctive biomarkers to comple-
ment the value of vascular invasion and other clinicopath-
ological data.
Our work re-confirms the prognostic value of clinico-
pathological variables regarding disease relapse of stage I
testicular germ cell tumor patients. Vascular invasion
significantly associated with relapse in the overall cohort
and significantly influenced relapse-free survival (includ-
ing in multivariable analysis), and this impact was main-
tained when considering only non-seminoma patients,
but not for seminoma patients, in line with previous
studies [34, 35]. Presence of embryonal carcinoma is also
associated with poorer relapse-free survival. This is in line
with previous knowledge which unequivocally support the
predictive value of vascular invasion assessment in non-
seminoma patients [5, 12, 36–46] and further suggest
amount of embryonal carcinoma as adjunctive in this con-
text [5]. For seminoma, however, other variables are ad-
vanced to help in clinical decision-making: tumor size and
rete testis invasion. In our series we did not however find
these variables to be informative regarding disease recur-
rence; despite the limited number of patients included,
this is in line with the systematic review of Boormans
et al. [14] showing that the prognostic power of these fea-
tures is still poor and cannot be reliably and blindly used
to determine therapeutic action. Remarkably, elevation of
HCG significantly associated with vascular invasion and it
also significantly impacted relapse-free survival, even
when adjusting for vascular invasion effect. It has been
suggested that HCG elevations in testicular germ cell tu-
mors (both seminomas and non-seminomas) positively
regulate the vascular endothelial growth factor (VEGF),
leading to vessel neoformation, which explains both the
association with vascular invasion status and the poor
prognostic value of this finding [47, 48].
The role of MIB-1 scoring as a prognostic marker in tes-
ticular germ cell tumors has been debatable, also because
of different methodologies and cutoffs used in its assess-
ment. While some studies demonstrated higher immu-
noexpression scores associating with poor prognosis
(using the 40 and 70% cutoffs) [30, 31], more recent stud-
ies were not able to validate these cutoffs and reported
this immunoexpression to be overall non-informative in a
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large cohort of stage I non-seminomas on surveillance, es-
pecially when adjusting to vascular invasion [21]. The dis-
tribution of MIB-1 staining proportions among these
studies were also variable, possibly due to the different
antibodies applied. In our work we could also not validate
the 40 and 70% cutoffs. However, patients with > 50%
scores experienced significantly poorer relapse-free sur-
vival, although the effect was again lost when adjusting for
vascular invasion status. Importantly, when focusing solely
on the subset of patients without vascular invasion, MIB
scoring of more than 50% identified a group of patients
with a worse clinical outcome. This finding, highlighted in
Fig. 3, constitutes a novelty compared to previous studies
mentioned above, and deserves validation in much larger
cohorts to confirm its clinical usefulness.
TEX19 is a recently characterized player within the
family of cancer testis antigens, which are normally
expressed in the germ cell compartment of the normal
Fig. 3 Biomarkers related to proliferation (MIB-1) and immune microenvironment (CXCL12) stratify risk groups in patients with and without
vascular invasion. Abbreviations: GCT – germ cell tumor; TGCT – testicular germ cell tumor
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testis, but also in a wide range of cancers, with current
evidence pointing towards an oncogenic function of
these proteins [49]. Planells-Palop et al. [26] revealed
that TEX19 regulates proliferation and analysis of The
Cancer Genome Atlas database shows it associates with
distinct clinical outcomes in several tumor models. The
authors evidenced cytoplasmic staining for the marker in
basal cells within seminiferous tubules, which seemed to
correspond to a subpopulation of Sertoli cells. This was
in line with findings of Zhong et al. and did not support
the role of this marker as a cancer testis antigen [50].
However, the former authors also evidence, by immuno-
fluorescence, foci of nuclear expression of TEX19 in
MAGE-A1-positive cells, corresponding to spermato-
gonia [26], a finding our study confirms by use of immu-
nohistochemistry, as depicted in Supplementary Fig. 1.
This supports the advanced role of TEX19 in germ cells,
and not only in Sertoli cells, thereby fulfilling the classi-
fication of a cancer testis antigen. In addition, they dem-
onstrate that this protein can accumulate both in the
cytoplasm and nucleus of several cell lines, and describe
staining in the nuclei of the germ cell tumor cell line
NTera-2 (representative of a non-seminoma), contrast-
ing to the absence of nuclear staining for this marker in
our cohort of 70 stage I primary tumors. NTera-2 cells
can easily develop signs of neural differentiation, which
could affect the subcellular location of the protein. In
our cohort we did find a weak cytoplasmic staining for
TEX19 in a minority of primary tumors (i.e., 14 non-
seminomas and one seminoma). The biological meaning
of this finding is still unknown but indicates TEX19 may
not behave solely as a cancer testis antigen. This bio-
marker was indeed advanced as contributing to tumor
cells proliferation; in our series of stage I patients its ex-
pression did not, however, significantly affect clinical
outcome, not did it impact disease-relapse.
The CXCL12/CXCR4 axis plays a role during male
germ cell development, with primordial germ cells ex-
pressing CXCR4 and migrating towards locations with
high CXCL12 content [51, 52]. In this line, there is ra-
tionale for exploring these markers in germ cell tumors,
since they are developmental cancers [53, 54]. In two
studies from the same group [21, 22] it was shown that
a CXCL12 gradient was able to stimulate migration of
germ cell tumor cells [22], and that non-seminoma stage
I patients on surveillance with higher CXCL12 immu-
noexpression in tumor cells exhibited significantly better
relapse-free survival, independently of vascular invasion
status [21]. Authors hypothesized that the constant sup-
ply of CXCL12 might abrogate a gradient that is neces-
sary to trigger migration. Our work, despite of using
similar cutoff values, could not reproduce these findings,
in line with recent observations by Fankhauser et al.
[19]. However, all studies, including ours, demonstrate
that CXCL12 is almost exclusively found in non-
seminomas, and we confirmed this on an in silico ana-
lysis of The Cancer Genome Atlas (TCGA) database
(Supplementary Fig. 6, p < 0.0001). So, we hypothesize
that CXCR4/CXCL12 axis activation should be relevant
for TGCT tumorigenesis. Indeed, Gilbert et al. demon-
strated that CXCR4 expression led to activation of the
PI3K-AKT and MEK-ERK pathways, constituting add-
itional data showing the relevance of activated RAS
pathway in TGCT tumorigenesis [22]. Given the known
influence of the microenvironment in testicular germ
cell tumors [28] we hypothesized that CXCL12 expres-
sion in stromal/inflammatory cells might also influence
the final tendency for tumor cells to migrate and invade.
Also, besides autocrine CXCL12 expression, peri-tumor
immune cells may be inducing CXCL12 expression in
the tumor cells they encase, in an attempt to prevent
dissemination; this has not been explored before. Indeed,
we found that non-seminoma patients with CXCL12
positivity in surrounding stromal/immune cells showed
a significantly improved relapse-free survival, which was
able to discriminate two risk groups within patients
showing vascular invasion (p = 0.015). This finding has
not been reported in previous works and deserves fur-
ther validation. We believe that the high expression
levels of CXCL12 in these cells immediately surrounding
the tumor nests may also abrogate the necessary gradi-
ent for triggering migration of tumor cells towards other
CXCL12-rich distant locations.
The receptor CXCR4 is present at the cell membrane,
can be sequestered into the cytoplasm, but recent evi-
dence also showed that it can translocate to the nucleus.
Accurate detection of nuclear CXCR4 depends greatly
on the antibody used and its ability to specifically target
this relevant epitope [55]. Nuclear expression of CXCR4
has been shown to impact prognosis in several tumor
models, associating both with poorer and improved out-
come [56–58]. To the best of our knowledge, this has
not been addressed in germ cell tumors. In our work,
cases with exclusively CXCR4 nuclear immunoexpres-
sion were significantly more frequent in seminomas and
significantly associated with better relapse-free survival.
However, again, the effect was not maintained in multi-
variable analysis. We hypothesize that the absence of
CXCR4 at the membrane renders the cell insensitive to
any available CXCL12 gradient, and so these tumors
may not migrate and invade.
Beta-catenin was demonstrated by Chovanec et al. as a
poor prognostic factor in testicular germ cell tumors;
the mechanism implied to be related to a suppressed im-
mune microenvironment [20]. Using the same approach
of the authors and applying a combined score of inten-
sity and percentage of stained cells, we confirmed that
the immunoexpression pattern is significantly lower in
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seminomas when compared to non-seminomas. Also, the
authors did not find a significant impact of beta-catenin
expression on relapse-free survival, including when strati-
fying the analysis for seminomas or non-seminomas only.
However, they included both gonadal and extra-gonadal
tumors, several disease stages and patients with metastatic
disease receiving adjuvant treatment. In our more strict
stage I surveillance setting we did find higher beta-catenin
immunoexpression to be significantly associated with the
event of relapse and a tendency for patients with higher
expression to show overall poorer relapse-free survival
(p = 0.045 and p = 0.056, respectively), which corroborates
the immune-suppressed microenvironment initially de-
scribed by the authors [20].
MECA-79 was documented to be ectopically expressed
in tumor cells of gastric cancer patients (28% of the cases),
which associated with poor prognostic features and poorer
disease-specific survival [23]. Its expression has not been
assessed in germ cell tumors to date. In our study, we
found MECA-79 not to be expressed in tumor cells of
both seminomas and non-seminomas. However, we spe-
cifically concentrated on the clinical setting of stage I dis-
ease on surveillance, with good prognosis, so it is possible
that its expression is restricted to higher stage, advanced
disease, like in the reported study on gastric cancer [23].
Moreover, MECA-79 has been used as a marker of the so-
called high endothelial venules, which occur naturally in
tertiary lymphoid organs and lymph nodes [59]. These
specialized vessels are frequently found in solid tumors
(demonstrated in colon, breast, lung and ovarian carcin-
oma and in malignant melanoma) and are thought to fa-
cilitate tumor infiltration by lymphocytes, contributing to
Fig. 4 Representative examples of immunoexpression patterns of MIB-1, TEX19 and Beta-catenin. a – Two distinct pure seminoma cases, one
with diffuse nuclear staining for MIB-1 (on the left) and another with < 50% positive tumor cells (on the right); b – A case of pure embryonal
carcinoma with 100% positivity for MIB-1; c – Faint cytoplasmic positivity for TEX19 in a pure yolk sac tumor with hyaline globules; d – Complete
absence of staining for TEX19 in a pure seminoma; e – Two distinct pure seminoma cases, one with diffuse, strong, membrane staining for Beta-
catenin (on the left) and another with very faint and discontinuous membrane staining in 20% of tumor cells, rendering a combined score≤ 100
(on the right). Notice the internal positive control (staining in capillary vessels within the tumor); f – Strong and diffuse membrane staining for
Beta-catenin in a mixed tumor composed of yolk sac tumor, embryonal carcinoma and teratoma, rendering a combined score > 100
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better prognosis [60]. In malignant melanoma, for in-
stance, a high density of such vessels was associated with
tumor regression and good prognostic features [24]. Our
work shows no presence of such MECA-79-positive ves-
sels in all testicular germ cell tumor samples included (in
the presence of staining of the positive control – human
tonsil – depicted in Supplementary Fig. 4), indicating a
limited role of this assessment as a predictive biomarker
in this tumor model.
One of the limitations of our work is its retrospective
nature and the relative small cohort size. However, the
power is the true surveillance cohort of 70 stage I pa-
tients (partly already described in [16]), avoiding con-
founding factors related to any treatment except initial
orchiectomy. Also, and because our cases derive from
several institutions across the Netherlands, our findings
do not reflect a selection bias due to inclusion of pa-
tients from a single center. Moreover, the classical prog-
nostic histopathological variables already known to be
informative in predicting relapse were re-confirmed in
this work, validating our cohort.
Conclusions
Overall, we believe that several protein biomarkers could
bring additional value for the prediction of relapse in
stage I testicular germ cell tumor patients, but further
studies, large, multicentric and prospective, with defined
methodology should be pursued before sound conclu-
sions with clinical robustness can be made. For the time
being, an accurate histopathological evaluation of the
Fig. 5 Illustrative examples of immunoexpression patterns of CXCL12 and CXCR4. a and b – Two cases with strong and diffuse membrane/
cytoplasmic staining for CXCL12 in tumor cells, a choriocarcinoma component of a mixed tumor (a) and a yolk sac tumor component of a mixed
tumor (b); c – A case of a pure embryonal carcinoma with absent immunoexpression of CXCL12 in tumor cells or in surrounding stromal/
inflammatory cells. Notice the internal positive control in the rete testis; d – Notice the contrast to this case, another pure embryonal carcinoma
with absent CXCL12 staining in tumor cells, but with abundant staining in surrounding stromal/immune cells in the tumor microenvironment, at
the periphery and within the tumor nests; e – Two cases with exclusive strong nuclear immunoexpression of CXCR4, a pure teratoma (on the
left) and a pure seminoma (on the right); f – Notice the contrast to these two cases of pure embryonal carcinomas, with a predominance of
cytoplasmic staining for CXCR4. Rare nuclei exhibited CXCR4 staining in these cases
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orchiectomy specimen by an experienced Pathologist
and a correct clinical assessment of the patient are the
most consistent tools for predicting patient outcome in
the daily routine.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12885-020-07220-6.
Additional file 1: Supplementary Table 1. Immunohistochemistry
method details.
Additional file 2: Supplementary Figure 1. TEX19 expression in
adjacent seminiferous tubules. TEX19 immunoexpression in normal
testicular parenchyma. Notice the strong cytoplasmic staining restricted
to the basal layer of the tubules, corresponding to Sertoli cells. Also
notice the small punctate foci of nuclear staining in spermatogonial cells
within the tubule (red arrows).
Additional file 3: Supplementary Figure 2. Kaplan-Meier curves re-
garding relapse-free survival in the stage I patient cohort on surveillance,
according to immunoexpression of: TEX19 (A), CXCL12 positivity in tumor
cells (B), and Beta-catenin combined score (C).
Additional file 4: Supplementary Figure 3. Representative examples
of immunoexpression patterns of several markers in the adjacent
testicular parenchyma. A – TEX19 cytoplasmic immunoexpression in
tubules containing germ cell neoplasia in situ (GCNIS), localizing mainly
to the basal layer in the position of Sertoli cells; B – TEX19 cytoplasmic
immunoexpression in tubules containing GCNIS, and complete absence
within tubules completely filled by GCNIS cells that contain no more
Sertoli cells (intratubular seminoma); C – Strong and exclusively nuclear
positivity for CXCR4 in seminiferous tubules adjacent to a seminoma.
Staining of stromal/inflammatory cells is also depicted; D – Beta-catenin
strong, diffuse, membrane/cytoplasmic immunoexpression in tubules
containing multilayer GCNIS. Notice the contrast to lower intensity mem-
brane staining in adjacent seminoma.
Additional file 5: Supplementary Figure 4. Representative examples
of immunostaining patterns of MECA-79. A and B – Evidence of MECA-
79-positive vessels within the positive control (human tonsil); C and D –
Complete absence of MECA-79 immunoexpression, either in tumor cells
(an example of an embryonal carcinoma is depicted) or in surrounding
vessels.
Additional file 6: Supplementary Figure 5. Immunoexpression of the
several markers in relation to time of storage of samples .
Additional file 7: Supplementary Figure 6. In silico analysis of
CXCL12 expression within TCGA database for testicular germ cell tumors.
mRNA expression levels from RNA-sequencing are plotted.
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